TITLE

Pacific Growth Sticks To Its Knitting

AUTHOR(S)
O'Connor, Colleen Marie
PUB. DATE
May 2006
SOURCE
Investment Dealers' Digest;5/15/2006, Vol. 72 Issue 19, p20
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the business success of Pacific Growth Equities LLC in the U.S. The company was a co-manager of a 40.9 million dollars initial public offering (IPO) for Novacea Inc. It has registered eight IPO worth of 502.5 million dollars. It has retained its focus on life sciences and technology as it launched a new group on clean technology and alternative energy.
ACCESSION #
20952144

 

Related Articles

  • Financings Roundup.  // BioWorld Today;12/27/2007, Vol. 18 Issue 249, p5 

    This article reports on the announcement made by Anesiva Inc. in 2007 that it closed its public offering of 11.1 million shares of common stock. Net proceeds totaled $47.7 million, including the additional 1.2 million shares sold to cover overallotments, and will be used for clinical trials and...

  • Financings Roundup.  // BioWorld Today;10/26/2007, Vol. 18 Issue 209, p2 

    The article reports on the plan of San Diego, California-based MediciNova Inc. to publicly offer 6 million shares of common stock. The company will grant underwriters a 30-day option to purchase up to an additional 900,000 shares to cover overallotments. Pacific Growth Equities LLC acts as...

  • NeuStar raises $600M in IPO. Dano, Mike // RCR Wireless News;7/4/2005, Vol. 24 Issue 27, p9 

    Reports on the amount raised by NeuStar Inc. from an initial public offering (IPO) in the U.S. Number of shares issued by the company; Comments of Pacific Growth Equities on NeuStar; Results of a report conducted by Thomson Venture Economics and the National Venture Capital Association on the...

  • BG Medicine joins crowded life science IPO queue with $80M filing.  // Medical Device Daily;8/7/2007, Vol. 11 Issue 149, p2 

    The article reports on the launch of an initial public offering (IPO) from Waltham, Massachusetts-based BG Medicine. The life-sciences company filed to raise $80 million, which it intends to use for discovery and development activities, including expanding and enhancing laboratory infrastructure...

  • Avigen Raises $27.6M For Neurology Programs.  // Bioworld Week;4/30/2007, Vol. 15 Issue 18, p5 

    The article reports on the fund raising of Avigen Inc. about $27.6 million in a public offering to fund development of its programs in neurological disorders in the U.S. The company sold 3.974 million shares at $6.94 per share, and underwriters Pacific Growth Equities LLC and UBS Investment Bank...

  • Financings Roundup.  // BioWorld Today;12/19/2007, Vol. 18 Issue 245, p7 

    The article reports on the terms set by Elixir Pharmaceuticals Inc. for its proposed initial public offering. Shares of the company will be sold as part of its plan. Underwriters that will have the option to purchase additional shares include Credit Suisse Securities LLC, Pacific Growth Equities...

  • Pay increases still healthy for nonfounder executives at private life sciences companies. Rychlik, Bruce // Nature Biotechnology;Apr2014, Vol. 32 Issue 4, p393 

    The article focuses on the salary increase for nonfounder executives at private life sciences companies. It says that 2013 version of CompStudy revealed that private companies saw a 52 life sciences initial public offerings (IPOs). It states that the survey shows compensation for positions...

  • IPO of LSP Life Sciences Fund on NYSE Euronext.  // Biomedical Market Newsletter;5/28/2011, p539 

    The article reports on the announcement made by LSP Advisory BV concerning its initial public offering (IPO) of the LSP Life Sciences Fund NV in Amsterdam, Netherlands. It mentions that the launching of the fund allows investors to obtain access to a blend of experience and expertise that are...

  • Endocyte, BG Slash IPO Prices but Shares Trade Up on Debut.  // Bioworld Week;2/14/2011, Vol. 19 Issue 7, p2 

    The article discusses the move of life sciences companies in the U.S. including Endocyte Inc. and BG Medicine Inc. to cut the prices of its initial public offering (IPO).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics